Gilead Sciences INC GILEAD SCIENCES ORD SHS
Gilead Sciences INC GILEAD SCIENC.../ US3755581036 /
0QYQ
2024-05-24 6:04:40 PM
|
Chg.
-
|
Volume |
Bid6:30:00 PM |
Ask6:30:00 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
66.42USD
|
-
|
6,526 Turnover: 96,741.02 |
-Bid Size: - |
-Ask Size: - |
102.98 bill.USD |
3.63% |
18.20 |
Business description
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
Management board & Supervisory board
CEO |
Daniel O’Day |
Management board |
Andrew Dickinson, Jyoti Mehra, Stacey Ma, Flavius Martin, Johanna Mercier, Cindy Perettie, Deborah H. Telman, Merdad Parsey |
Supervisory board |
Daniel O’Day, Jacqueline K. Barton, Jeffrey A. Bluestone, Sandra J. Horning, Kelly A. Kramer, Harish Manwani, Anthony Welters, Ted W. Love, Javier J. Rodriguez |
Company data
Name: |
Gilead Sciences Inc. |
Address: |
333 Lakeside Drive,Foster City, California 94404, USA |
Phone: |
+1-650-574-3000 |
Fax: |
+1-650-578-9264 |
E-mail: |
corporate_developmen...ad.com
corporate_development@gilead.com
|
Internet: |
www.gilead.com |
Industry: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Sub sector: |
Pharmaceuticals |
End of financial year: |
12-31 |
Free Float: |
99.89% |
IPO date: |
1992-01-22 |
Company calendar
CW 39 | 2024-09-27
Dividend Payment
|
CW 45 | 2024-11-07
Interim Report 3rd Quarter/9 Months
|
Main Shareholders
Others |
|
55.91% |
BlackRock Inc. |
|
9.86% |
Vanguard Group |
|
8.98% |
Capital World Investors |
|
6.69% |
CAPITAL RESEARCH GLOBAL INVESTOR |
|
4.79% |
State Street Corporation |
|
4.78% |
Dodge & Cox |
|
2.67% |
GEODE CAPITAL MANAGEMENT LLC |
|
2.03% |
Wellington Management Group |
|
1.50% |
Others |
|
2.80% |